Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NYSE:CYBN NASDAQ:ORKA NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$568.27M2.382.10 million shs1.20 million shsCYBNCybin$6.09+1.3%$7.33$4.81▼$13.88$143.66M0.68350,935 shs539,778 shsORKAOruka Therapeutics$15.40-4.6%$14.57$5.49▼$31.13$576.73M-0.26238,221 shs69,090 shsXNCRXencor$8.60+1.2%$8.31$6.92▼$27.24$613.35M0.82766,468 shs791,753 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%CYBNCybin-4.30%+0.50%-21.23%-28.02%+1,528.73%ORKAOruka Therapeutics+2.41%+7.88%+15.77%+28.58%-45.48%XNCRXencor+1.67%+1.55%+9.68%-7.51%-59.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$7.74-0.9%$7.51$5.90▼$29.61$568.27M2.382.10 million shs1.20 million shsCYBNCybin$6.09+1.3%$7.33$4.81▼$13.88$143.66M0.68350,935 shs539,778 shsORKAOruka Therapeutics$15.40-4.6%$14.57$5.49▼$31.13$576.73M-0.26238,221 shs69,090 shsXNCRXencor$8.60+1.2%$8.31$6.92▼$27.24$613.35M0.82766,468 shs791,753 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas-0.26%+2.63%+15.02%+5.68%-68.62%CYBNCybin-4.30%+0.50%-21.23%-28.02%+1,528.73%ORKAOruka Therapeutics+2.41%+7.88%+15.77%+28.58%-45.48%XNCRXencor+1.67%+1.55%+9.68%-7.51%-59.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.55Moderate Buy$19.76155.34% UpsideCYBNCybin 3.25Buy$85.001,295.73% UpsideORKAOruka Therapeutics 3.20Buy$40.38162.18% UpsideXNCRXencor 2.67Moderate Buy$22.25158.72% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, ORKA, XNCR, and ARVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025XNCRXencorBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$23.00 ➝ $12.009/2/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.008/21/2025XNCRXencorRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$32.00 ➝ $15.008/18/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.008/12/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$40.008/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $15.008/7/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$33.00 ➝ $27.008/7/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$31.00 ➝ $26.007/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.16N/AN/A$8.17 per share0.95CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/AXNCRXencor$110.49M5.55N/AN/A$9.63 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)CYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest CYBN, ORKA, XNCR, and ARVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.645.64CYBNCybinN/A24.2424.24ORKAOruka TherapeuticsN/A27.4227.42XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CYBNCybin17.94%ORKAOruka Therapeutics56.44%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas4.73%CYBNCybin15.00%ORKAOruka Therapeutics24.69%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42073.42 million69.95 millionOptionableCYBNCybin5023.59 million17.96 millionNot OptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/AXNCRXencor28071.32 million67.93 millionOptionableCYBN, ORKA, XNCR, and ARVN HeadlinesRecent News About These CompaniesJacobs Levy Equity Management Inc. Buys 384,509 Shares of Xencor, Inc. $XNCRSeptember 10 at 5:04 AM | marketbeat.com155,580 Shares in Xencor, Inc. $XNCR Bought by Cubist Systematic Strategies LLCSeptember 9 at 4:10 AM | marketbeat.comTrexquant Investment LP Acquires 50,119 Shares of Xencor, Inc. $XNCRSeptember 8, 2025 | marketbeat.comRBC Cuts Xencor (XNCR) Price Target but Keeps Outperform RatingSeptember 8, 2025 | msn.comXencor (NASDAQ:XNCR) Cut to Neutral at Bank of AmericaSeptember 6, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Shares Gap Down Following Analyst DowngradeSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Cut to "Neutral" at Bank of AmericaSeptember 5, 2025 | marketbeat.comBVF Inc. IL Buys 451,381 Shares of Xencor, Inc. $XNCRSeptember 5, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Shares Gap Down After Analyst DowngradeSeptember 5, 2025 | americanbankingnews.comXencor (NASDAQ:XNCR) Trading Up 6% - What's Next?September 4, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Holdings in Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comB of A Securities Downgrades Xencor (XNCR)September 4, 2025 | msn.comPanagora Asset Management Inc. Acquires 260,124 Shares of Xencor, Inc. $XNCRSeptember 4, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Xencor (NASDAQ:XNCR)September 4, 2025 | americanbankingnews.comXencor downgraded to Neutral from Buy at BofASeptember 3, 2025 | msn.comBeyond The Numbers: 4 Analysts Discuss Xencor StockSeptember 3, 2025 | benzinga.comXencor downgraded to Neutral at BofA on long development timelinesSeptember 3, 2025 | msn.comBraidwell LP Boosts Stock Position in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNantahala Capital Management LLC Purchases New Shares in Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Purchases 34,765 Shares of Xencor, Inc. $XNCRSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, ORKA, XNCR, and ARVN Company DescriptionsArvinas NASDAQ:ARVN$7.74 -0.07 (-0.90%) Closing price 04:00 PM EasternExtended Trading$7.77 +0.03 (+0.39%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Cybin NYSE:CYBN$6.09 +0.08 (+1.33%) Closing price 04:00 PM EasternExtended Trading$6.13 +0.04 (+0.66%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Oruka Therapeutics NASDAQ:ORKA$15.40 -0.75 (-4.64%) Closing price 04:00 PM EasternExtended Trading$15.40 +0.00 (+0.03%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Xencor NASDAQ:XNCR$8.60 +0.10 (+1.18%) Closing price 04:00 PM EasternExtended Trading$8.56 -0.04 (-0.52%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
